Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway

Oncotarget

Volumn 6, Issue 34, 2015, Pages 36041-36052

  Murali, Rajmohan ^a   Chandramohan, Raghu ^a   Möller, Inga ^b   Scholz, Simone L ^b   Berger, Michael ^a   Huberman, Kety ^a   Viale, Agnes ^a   Pirun, Mono ^a   Socci, Nicholas D ^a   Bouvier, Nancy ^a   Bauer, Sebastian ^b   Artl, Monika ^c   Schilling, Bastian ^b   Schimming, Tobias ^b   Sucker, Antje ^b   Schwindenhammer, Benjamin ^b   Grabellus, Florian ^b   Speicher, Michael R ^c   Schaller, Jörg ^d   Hillen, Uwe ^b   Schadendorf, Dirk ^b   Mentzel, Thomas ^e   Cheng, Donavan T ^a   Wiesner, Thomas ^a,c   Griewank, Klaus G ^b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d Dermatopathology Duisburg   (Germany)

^e Dermatopathologische Gemeinschaftspraxis   (Germany)

Author keywords

Angiosarcoma; Genetics; MAPK pathway; MYC

Indexed keywords

B RAF KINASE; CRK LIKE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; RAF PROTEIN;

ADULT; AGED; ANGIOSARCOMA; ARTICLE; BRAF GENE; CDKN2A GENE; CONTROLLED STUDY; CRAF GENE; CRKL GENE; ENZYME ACTIVATION; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MAPK1 GENE; MIDDLE AGED; NEXT GENERATION SEQUENCING; NF1 GENE; ONCOGENE; ONCOGENE C MYC; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PLCG1 GENE; PTPRB GENE; SIGNAL TRANSDUCTION; TP53 GENE; TUMOR SUPPRESSOR GENE; VERY ELDERLY; ENZYMOLOGY; GENETICS; METABOLISM; PROGNOSIS; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ENZYME ACTIVATION; FEMALE; HEMANGIOSARCOMA; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84946893390     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5936     Document Type: Article

References (49)

1. Young RJ, Brown NJ, Reed MW, Hughes D and Woll PJ. Angiosarcoma. The lancet oncology. 2010; 11:983-991.
2. Frith AE, Hirbe AC and Van Tine BA. Novel pathways and molecular targets for the treatment of sarcoma. Current oncology reports. 2013; 15:378-385.
3. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachere NE, Edgar MA, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27:3133-3140.
4. von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW and Borden E. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer. 2012; 118:770-776.
5. Ray-Coquard I, Italiano A, Bompas E, Le Cesne A, Robin YM, Chevreau C, Bay JO, Bousquet G, Piperno-Neumann S, Isambert N, Lemaitre L, Fournier C, Gauthier E, Collard O, Cupissol D, Clisant S, et al. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). The oncologist. 2012; 17:260-266.
6. Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM and Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2013; 24:257-263.
7. Azzariti A, Porcelli L, Mangia A, Saponaro C, Quatrale AE, Popescu OS, Strippoli S, Simone G, Paradiso A and Guida M. Irradiation-induced angiosarcoma and anti-angiogenic therapy: a therapeutic hope? Experimental cell research. 2014; 321:240-247.
8. Yoo KH, Kim HS, Lee SJ, Park SH, Kim SJ, Kim SH, La Choi Y, Shin KH, Cho YJ, Lee J and Rha SY. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC cancer. 2015; 15:154.
9. Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S and Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. Nature reviews Cancer. 2011; 11:541-557.
10. Mertens F, Panagopoulos I and Mandahl N. Genomic characteristics of soft tissue sarcomas. Virchows Archiv: an international journal of pathology. 2010; 456:129-139.
11. Mertens F, Antonescu CR, Hohenberger P, Ladanyi M, Modena P, D'Incalci M, Casali PG, Aglietta M and Alvegard T. Translocation-related sarcomas. Seminars in oncology. 2009; 36:312-323.
12. Manner J, Radlwimmer B, Hohenberger P, Mossinger K, Kuffer S, Sauer C, Belharazem D, Zettl A, Coindre JM, Hallermann C, Hartmann JT, Katenkamp D, Katenkamp K, Schoffski P, Sciot R, Wozniak A, et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. The American journal of pathology. 2010; 176:34-39.
13. Mentzel T, Schildhaus HU, Palmedo G, Buttner R and Kutzner H. Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2012; 25:75-85.
14. Guo T, Zhang L, Chang NE, Singer S, Maki RG and Antonescu CR. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes, chromosomes & cancer. 2011; 50:25-33.
15. Shon W, Sukov WR, Jenkins SM and Folpe AL. MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2014; 27:509-515.
16. Antonescu CR, Yoshida A, Guo T, Chang NE, Zhang L, Agaram NP, Qin LX, Brennan MF, Singer S and Maki RG. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer research. 2009; 69:7175-7179.
17. Cornejo KM, Deng A, Wu H, Cosar EF, Khan A, St Cyr M, Tomaszewicz K, Dresser K, O'Donnell P and Hutchinson L. The utility of MYC and FLT4 in the diagnosis and treatment of postradiation atypical vascular lesion and angiosarcoma of the breast. Human pathology. 2015; 46:868-875.
18. Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P, Gundem G, Wedge DC, Ramakrishna M, Cooke SL, Pillay N, Vollan HK, Papaemmanuil E, Koss H, Bunney TD, Hardy C, Joseph OR, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nature genetics. 2014; 46:376-379.
19. Kunze K, Spieker T, Gamerdinger U, Nau K, Berger J, Dreyer T, Sindermann JR, Hoffmeier A, Gattenlohner S and Brauninger A. A Recurrent Activating PLCG1 Mutation in Cardiac Angiosarcomas Increases Apoptosis Resistance and Invasiveness of Endothelial Cells. Cancer research. 2014; 74:6173-6183.
20. Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, Chandramohan R, Liu ZY, Won HH, Scott SN, Brannon AR, O'Reilly C, Sadowska J, Casanova J, Yannes A, Hechtman JF, et al. Memorial Sloan KetteringIntegrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based NextGeneration Sequencing Clinical Assay for Solid Tumor Molecular Oncology. The Journal of molecular diagnostics: JMD. 2015; 17:251-264.
21. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine. 2012; 366:2443-2454.
22. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England journal of medicine. 2012; 366:2455-2465.
23. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, et al. Nivolumab plus ipilimumab in advanced melanoma. The New England journal of medicine. 2013; 369:122-133.
24. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010; 363:711-723.
25. Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M and Wolchok JD. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015; 33:1191-1196.
26. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R, et al. Mutations in GNA11 in uveal melanoma. The New England journal of medicine. 2010; 363:2191-2199.
27. Murali R, Wiesner T, Rosenblum MK and Bastian BC. GNAQ and GNA11 mutations in melanocytomas of the central nervous system. Acta neuropathologica. 2012; 123:457-459.
28. Kusters-Vandevelde HV, Klaasen A, Kusters B, Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, Reifenberger G, Wesseling P and Blokx WA. Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta neuropathologica. 2010; 119:317-323.
29. Shirley MD, Tang H, Gallione CJ, Baugher JD, Frelin LP, Cohen B, North PE, Marchuk DA, Comi AM and Pevsner J. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. The New England journal of medicine. 2013; 368:1971-1979.
30. Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, Zhao L, Peyman G, Ouyang H, Jiang W, Zhao J, Chen X, Zhang L, Wang CY, Bastian BC, Zhang K, et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer cell. 2014; 25:822-830.
31. Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino G, Sodhi A, Chen Q and Gutkind JS. Hippoindependent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer cell. 2014; 25:831-845.
32. Chen X, Wu Q, Tan L, Porter D, Jager MJ, Emery C and Bastian BC. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene. 2013.
33. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ and Ponten J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 1991; 88:10124-10128.
34. Ouhtit A, Ueda M, Nakazawa H, Ichihashi M, Dumaz N, Sarasin A and Yamasaki H. Quantitative detection of ultraviolet-specific p53 mutations in normal skin from Japanese patients. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1997; 6:433-438.
35. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, Rutten A, Palmedo G, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nature genetics. 2011; 43:1018-1021.
36. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:20007-20012.
37. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, et al. The landscape of somatic copynumber alteration across human cancers. Nature. 2010; 463:899-905.
38. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R and Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome biology. 2011; 12:R41.
39. Geigl JB and Speicher MR. Single-cell isolation from cell suspensions and whole genome amplification from single cells to provide templates for CGH analysis. Nature protocols. 2007; 2:3173-3184.
40. Krueger F. (2013). Trim Galore: A wrapper script to automate quality and adapter trimming as well as quality control.
41. Li H and Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25:1754-1760.
42. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M and DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome research. 2010; 20:1297-1303.
43. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES and Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature biotechnology. 2013; 31:213-219.
44. Rausch T, Zichner T, Schlattl A, Stutz AM, Benes V and Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012; 28:i333-i339.
45. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L and Wilson RK. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome research. 2012; 22:568-576.
46. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, Kok CY, Jia M, De T, Teague JW, Stratton MR, McDermott U, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic acids research. 2015; 43:D805-811.
47. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling. 2013; 6:pl1.
48. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012; 2:401-404.
49. Coindre JM. Grading of soft tissue sarcomas: review and update. Archives of pathology & laboratory medicine. 2006; 130:1448-1453.